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Abstract
Limiting beta amyloid (Ab) production could become an
important therapeutic target in Alzheimer’s disease (AD). Ab is
derived by the sequential cleavage of amyloid precursor pro-
tein (APP) by b- and c-secretases. A double missense
mutation in APP found in a Swedish pedigree (APPsw) ele-
vates Ab40 and Ab42 production. Ab production and, there-
fore, b-secretase cleavage of APPsw reportedly occur in the
endoplasmic reticulum (ER), Golgi and endocytic compart-
ments. However, the relative contribution of b-secretase
cleavage occurring in each compartment has not been
determined. Experiments described here use a novel ELISA to
measure the b-cleaved product, APPswb. Using this ELISA,
we provide new information regarding the relative amount of
b-secretase cleavage of APPsw that occurs in secretory and
endocytic pathways. Using a dilysine retrieval motif to retain
APPsw in the ER, we discovered that less than 15% of the
b-secretase cleavage was still detected. Experiments utilizing
endocytosis-impaired mutants of APPsw revealed that little or
no b-secretase cleavage of APPsw appears to take place
through endocytosis. Surprisingly, deletion of the entire cyto-
plasmic tail increased both APPswb and Ab secretion, sug-
gesting that protein interactions with this region normally
impede b-secretase cleavage. These results suggest that
APPsw is cleaved by b-secretase late in the secretory path-
way.
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Amyloid precursor protein (APP) is processed into Ab40 and
Ab42, by b- and c-secretases, which, respectively, cleave
within the extracellular and the transmembrane regions of
this type I integral membrane protein (for review see Selkoe
1998). Alzheimer’s disease (AD) is hypothesized to result
from the aggregation and deposition of these peptides into
amyloid plaques in brain. A double missense mutation in
APP identified in a Swedish pedigree with early onset
familial Alzheimer’s disease (FAD) (APPsw; K651N/
M652L) enhances cleavage by b-secretase. This, in turn,
increases both Ab40 and Ab42 secretion (Citron et al. 1994;
Haass et al. 1995).
To develop strategies for therapeutic treatment of AD, a
thorough understanding of all the molecular mechanisms
capable of generating amyloid peptides is required. APP
bearing the Swedish mutation is an important biochemical
tool since it has been established that expression of APPsw
in non-neuronal cells more closely mimics processing of
APPwt by neurons (Forman et al. 1997). A complete
understanding of amyloid generation will ensure that a
treatment is also capable of blocking alternate secondary
pathways that may become major sites of Ab generation in
neurons if only the primary site is inhibited. Such mech-
anisms include determining the cellular location(s) of b- and
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c-secretase cleavage of APPsw. However, determining the
cellular site(s) of Ab peptide derivation is more complex than
originally thought. Production of Ab in Chinese hamster
ovary (CHO) cells involves internalization of APP from the
cell surface (Koo and Squazzo 1994). Furthermore, Ab
secretion is severely decreased in non-neuronal cells expres-
sing APP constructs possessing cytoplasmic tail mutations
that impair endocytosis (Perez et al. 1999). APPsw process-
ing is different from APP in that blocking endocytosis of the
Swedish mutant by deleting the cytoplasmic internalization
signal still permits production of Ab peptide (Citron et al.
1995). This suggests that amyloid peptides could be
generated from APPsw within the secretory pathway. How-
ever, other experiments revealed that Ab peptide could also
be derived through processing of APPsw endocytosed from
the cell surface in addition to the secretory pathway (Perez
et al. 1996). Prior to the studies presented here, it was
unclear how much the secretory and endocytic pathways
contribute to Ab peptide production from APPsw.
The specific locations of intracellular amyloid peptide
generation within the secretory pathway may be distinctly
different for Ab40 and Ab42. Treating HEK 293 cells with
brefeldin A (BFA) to accumulate APP within the endoplas-
mic reticulum (ER) results in increased generation of
intracellular Ab peptides that terminated at amino acid 42,
but not at 40 (Wild-Bode et al. 1997). Similarly, treating
human NT2 neurons with BFA eliminated production of
intracellular Ab40 but not Ab42 (Cook et al. 1997). Indeed,
evidence of b-secretase cleavage in the ER has been
described in NT2 neurons (Chyung et al. 1997; Skovronsky
et al. 1998), hippocampal neurons (Hartmann et al. 1997;
Annaert et al. 1999) and fibroblasts isolated from PS-1
knockout mice (Xia et al. 1998). Recently, an enzyme with
all the characteristics of b-secretase has been identified and
appears to localize to the late Golgi and endosomes (Hussain
et al. 1999; Vassar et al. 1999; Yan et al. 1999; Haniu et al.
2000). Thus, evidence of b-secretase activity has been
reported within the endocytic pathway as well as within the
ER, the Golgi and trans Golgi network of the secretory
pathway in neuronal and non-neuronal cells. Determining the
relative amount of b-secretase cleavage of APPsw occurring
within each of these subcellular compartments would
enhance our understanding of the mechanisms of Ab peptide
generation.
We developed an ELISA capable of measuring APPswb, a
direct product of b-secretase cleavage of APPsw (Steinhilb
et al. 2001). In experiments described here utilizing the
APPswb ELISA in conjunction with endocytosis-impaired
APPsw mutants, we measured the relative contribution of
b-secretase cleavage occurring in both the secretory and
endocytic pathways. We also determined the relative amount
of b-secretase activity occurring within the early secretory
compartments by restricting movement of APPsw out of the
ER and cis Golgi. Finally, we report the surprising finding
that deletion of the cytoplasmic tail of APPsw significantly
increased cleavage by b-secretase. This suggests that
cytoplasmic proteins that interact with the carboxyl terminal
tail of APPsw affect its vulnerability to cleavage by
b-secretase.
Materials and methods
Cell lines, expression systems, and antibodies
Human endothelial kidney 293 (HEK293), Chinese hamster ovary
K1 (CHOK1), and mouse neuroblastoma (N2a) cells (American
Type Culture Collection, Rockville, MD, USA) were used for
transient transfections. All cell lines were grown in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal calf
serum, glutamine, non-essential amino acids (Life Technologies,
Inc., Rockville, D, USA) and penicillin/streptomycin/fungizone
(BioWhittaker, Inc., Walkersville, MD, USA) as described elsewhere
(Yang et al. 1998). For transfection experiments, cells were seeded
1 day prior to use at 1 · 106 cells/6-cm dish and transfected with
LipofectAMINE (Life Technologies, Inc.) reagent as described by
the manufacturer. APPsw containing a carboxyl-terminal double
lysine motif (KK) was engineered with two single-base changes
using PCR site-directed mutagenesis resulting in a QM to KK
modification at amino acids 747 and 748, respectively (Q747K/
M748K; APP-751 isoform numbering) similar to Chyung et al.
(1997). The Swedish mutation (K651M/N652L) was introduced into
the APP YENP mutants (kindly provided by Dr R.G. Perez,
University of Pittsburgh) and all mutants were cloned into the
pCDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA,
USA). All resulting cDNAs were sequenced to verify that only the
correct mutational changes were made. The monoclonal antibody
22C11 was purchased from Roche Molecular Biochemicals (Indi-
anapolis, IN, USA; Anti-Alzheimer Precursor Protein A4) and
recognizes amino acids 60–100 of the amino terminus. 8E5 is a
mouse monoclonal antibody raised to amino acids 444–592 of
human APP that does not react with mouse APP and was a generous
gift from Dr D. Schenk (Elan Pharmaceuticals).
Pulse-chase analysis, immunoprecipitation, electrophoresis,
and western blotting
Forty-four hours after transient transfection, cells were washed in
Dulbecco’s phosphate-buffered saline (PBS; Life Technologies,
Inc.) and incubated in cysteine-free/methionine-free DMEM (Life
Technologies, Inc.) for 30 min. One 6-cm plate containing 2 · 106
cells was used per sample. Cells were labeled with [35S]methionine/
[35S]cysteine (50 lCi/mL; ICN Pharmaceuticals, East Hill, NY,
USA) for 60 min. Labeling was terminated by washing the cells
with PBS and replacing the medium with DMEM containing
unlabeled methionine and cysteine for the appropriate chase time
(0–12 h), followed by lysis of cells. Cell lysates were prepared as
previously described (Yang et al. 1998). Total protein in lysates was
quantified (BCA Protein Assay, Pierce Chemicals, Rockford, IL,
USA). Specific radiolabeled proteins were immunoprecipitated,
separated on an 8% sodium dodecyl sulfate polyacrylamide gel
(SDS–PAGE) and detected by fluorography. Western blot analysis
was conducted with the monoclonal antibody, 22C11, as previously
described (Yang et al. 1998).
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ELISAs
Unless otherwise noted, conditioned medium was collected from
transiently transfected cells in the 16 h between 24- and 40-h post-
transfection. The ELISA is characterized elsewhere (Steinhilb et al.
2001) but, briefly, this assay employs a capture antibody (a931) that
recognizes the neo-epitope of the N-terminal fragment (NTF) of
APPsw that is generated upon b-secretase cleavage. The a931
antibody does not cross-react with the wild-type sequence, nor does
it recognize APPsw in the context of the full-length protein
(Steinhilb et al. 2001). Following capture, 8E5, a monoclonal
antibody specific for primate APP, is used to detect b-cleaved
APPsw. A horseradish peroxidase-conjugated anti-mouse immuno-
globulin antibody is used to develop the ELISA as described
(Steinhilb et al. 2001). A similar ELISA was adapted to measure
full-length APP (and APPsw) by replacing the a931 antibody with
another anticarboxyl terminal, a945 (Steinhilb et al. 2001). Samples
for both the #931 and #945 ELISA were collected within the linear
range of each assay (25 lL conditioned media, 10 lg total lysate).
ELISA samples were measured in triplicate wells and each
experiment was conducted at least three times except where noted.
The Ab40 ELISA was conducted as described (Yang et al. 1998).
Results
Confining APP to early secretory compartments extends the
half-life of the immature incompletely glycosylated form. We
sought to determine more accurately the relative amounts of
b-secretase cleavage of APPsw occurring in the early and
late secretory pathway as well as in the endocytic pathway.
We sought to measure b-secretase cleavage in the ER by
introducing an ER retrieval motif directly into APP. The
introduction of a dilysine sequence to the cytoplasmic region
of a type I transmembrane protein causes its net retention in
the ER (Jackson et al. 1993; Pond et al. 1995). Conse-
quently, the dilysine motif was introduced at the same site in
APP as described by Chyung et al. (1997) using PCR site-
directed mutagenesis.
If introduction of an ER retrieval signal to APP effectively
retains APP in the ER, then this should specifically prolong the
half-life of the immature, N-linked glycosylated form of APP.
To test this prediction, transiently transfected (Tf) HEK293
cells were pulse-labeled with [35S]-methionine/cysteine for
1 h and chased over a period of 12 h. A 1-h pulse was found to
be optimal for labeling and monitoring the metabolism of both
immature and mature APP. Radiolabeled APP that had been
immunoprecipitated (IP) from lysates was resolved by SDS–
PAGE. After chasing for just 1 h, the amount of both mature
(M) and immature (I) APP was greatly decreased for cells
transfected with APP alone (Fig. 1a). This result demonstrates
that transiently expressed APP has a half-life of less than 1 h
that is similar to previous studies (Weidemann et al. 1989).
Experiments were also performed to determine if retention
in the ER by addition of a dilysine retrieval motif to APP
(APPKK) (see Fig. 6) was sufficient to extend the half-life of
immature, N-linked glycosylated APP. As with APP alone,
HEK293 cells were transiently transfected with APPKK and
subjected to pulse-chase analysis (Fig. 1d). After a 1-h label,
immature APP was the predominant form observed, which is
consistent with the retention of APPKK in the ER of these
cells. This illustrates the efficiency of the dilysine motif in
APPKK to retain it in the ER. Compared to APP (Fig. 1a),
the half-life of immature APPKK (Fig. 1d) was greatly
extended. The immature form of APPKK contains N-linked
carbohydrates and is localized to the endoplasmic reticulum
as indicated by glycosidase treatment and differential
centrifugation (M. L. Steinhilb and J. R. Gaut, unpublished
data). Thus, these results demonstrate that introducing a
dilysine retrieval motif into the cytoplasmic region is
sufficient to retain immature APPKK in the ER.
The Swedish form of APP (APPsw) enhances cleavage by
b-secretase, causing an increase in both Ab40 and Ab42
relative to APP (Citron et al. 1994). To further characterize
the effect of ER retrieval on maturation and processing of
APP, the dilysine motif was also added to Swedish APP
(APPswKK) and compared to wild-type APP and APPKK.
HEK293 (Figs 2a,b) and N2a (Figs 2c,d) cells were transi-
ently transfected with APP, APPsw, APPKK, or APPswKK
and labeled with [35S]-methionine/cysteine for 1 h. Full-
length molecules were immunoprecipitated from the result-
ing cell lysates and b- or a-secretase cleaved fragments were
immunoprecipitated from conditioned media with the amino
terminal-specific Karen antibody. In cells transfected with
APPKK or APPswKK there is only a trace of the mature
form (Fig. 2a and c, lanes 2 and 4) compared to APP and
APPsw (Fig. 2a and c, lanes 1 and 3, respectively). This
indicates that like APPKK, APPswKK is efficiently retained
in the ER/IC of both HEK293 and the mouse neuroblastoma
cell line, N2a. Because Karen antibody recognizes human
APP, the small amount of mature fully glycosylated protein
recovered in HEK293 transfections (Fig. 2a) with APPKK
Fig. 1 Pulse-chase analysis indicates that ER retention is sufficient to
extend the half-life of immature APP. HEK293 cells were pulse-labeled
with [35S]-methionine/cysteine for 1 h and chased in excess unlabeled
methionine and cysteine. Radiolabeled lysates were immunoprecipi-
tated (IP) with either Karen (A, B and D) or aBiP antibody (C) and
resolved by SDS–PAGE. (a) Transient transfection with APP: imma-
ture (I) and mature (M) APP are indicated. (b) Expression of the
dilysine retrieval motif (APPKK) results in production of immature APP
but not the mature form, consistent with retention of APPKK in the ER.
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and APPswKK may be endogenous APP. Restriction to the
ER/IC using the dilysine retrieval signal also impeded the
secretion of the soluble APP and APPsw fragments into
conditioned media in HEK293 and N2a cells (Fig. 2b and d,
respectively). Similar results were also obtained in CHOK1
cells (data not shown). We conclude that maturation is
impaired when a dilysine retrieval motif is added to either
APP or APPsw. In turn, this block in maturation decreased,
but did not eliminate the subsequent secretion of cleaved
amino terminal fragments (NTFs) due to retention of full
length APPswKK in the ER/IC. Furthermore, these data
establish that in both neuronal and non-neuronal cell lines,
Swedish APP and wild-type APP undergo similar processing
and metabolic fates.
Restriction of APPsw to the ER/IC strongly inhibits
b-secretase cleavage
The studies thus far have shown that addition of a dilysine
retrieval signal can effectively confine APPsw to the ER/IC.
Furthermore, we found that retention in the ER impeded, but
did not eliminate, secretion of NTFs. Therefore, experiments
were next conducted to determine the proportion of b-secre-
tase cleavage occurring when APPsw is retained in the ER.
Our laboratory recently developed and optimized an ELISA
to measure b-secretase cleavage of APPsw (Steinhilb et al.
2001 and Materials and methods). This previously charac-
terized ELISA is highly sensitive and specific to b-secretase
cleaved APPsw and not b-secretase cleaved endogenous APP
(Steinhilb et al. 2001). In addition, it does not recognize
a-secretase cleaved APPsw or endogenous APP. Thus, we
used this assay to first determine how much b-secretase
cleavage occurred when APPsw was retained in the ER.
If a small amount of b-secretase cleavage occurs in the
ER/IC, then it should be detectable when APPsw is retained
in this compartment by introducing a dilysine retrieval motif.
HEK293 and CHOK1 cells were transiently transfected with
empty vector, APPwt, APPsw, or APPswKK. Secreted
APPswb was measured in conditioned media using the
#931 ELISA. In both CHOK1 and HEK293 cells transfected
with APPwt a slight elevation of signal above empty vector
was measurable (Fig. 3a). Thus, this constituted the back-
ground for the ELISA in subsequent analysis. Compared to
APPsw, b-secretase cleavage of APPswKK was significantly
decreased ( p < 0.001) in both HEK293 and CHOK1 cells.
However, a small amount of b-secretase cleaved APPswKK
was reproducibly detected in the conditioned media. The
amount of APPswb detected in the condition medium of
APPswKK-transfected HEK293 and CHOK1 cells was about
9% and 14%, respectively, of the amount measured when the
same cells were expressing similar levels of APPsw. It was
possible that more APPswb was derived in the early secretory
pathway, but this pool was not secreted from the cell.
Therefore, intracellular APPswb (iAPPswb) was immuno-
precipitated from CHOK1 cell lysates with #931 and
immunoblotted with 22C11 (Fig. 3b). Densitometric analysis
revealed that cells expressing APPswKK contained about
15% of the amount of iAPPswb present in APPsw expressing
cells. Thus, the decrease in secreted APPswb in APPswKK
expressing cells is not due to intracellular accumulation of the
cleaved product. Furthermore, APPswb production by cells
expressing APPswKK was comparatively the same whether
measured intracellularly or after secretion in the media.
The #945 antibody, used to capture full-length APP, did
not recognize APPKK, which precluded using the ELISA to
measure cellular APP levels. To verify equivalent expression
of the APP mutants, lysates from transiently transfected cells
were immunoprecipitated with 8E5 antibody, which recog-
nizes an epitope in the lumenal domain of APP. The
immunoprecipitated full-length protein was identified by
western blot using 22C11 (Fig. 3c). Although Fig. 3(c)
would suggest a more significant increase, densitometric
analysis of western blots indicated that protein expression
levels of APPswKK are about 5% greater than APPsw.
Fig. 2 Addition of a dilysine retrieval sequence to both the wild-type
and the Swedish form of APP blocks maturation and secretion of
cleaved fragments. HEK293 (a,b) and N2a (c,d) cells were transi-
ently transfected with pCDAPP, pCDAPPKK, pCDAPPsw, or
pCDAPPswKK. Cells were labeled with [35S]-methionine/cysteine for
1 h and cell lysates (a,c) were immunoprecipitated with Karen anti-
body. Both the a- and b-secretase cleaved soluble fragments were
immunoprecipitated from conditioned media (b,d) by Karen antibody
and resolved as a single diffuse band. The mature (M) and immature
(I) full-length forms immuno-isolated from HEK293 and N2a cell
lysates are indicated in (a) and (c), respectively.
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Determining the amount of b-secretase cleavage of APPsw
occurring in the secretory and endocytic pathways. b-secre-
tase cleavage of APPsw occurs in both the secretory and
endocytic pathways (Perez et al. 1996). However, the
relative contributions by these two pathways to the total
amount of APPswb secreted into the medium is uncertain.
Using our specific sandwich ELISA, we sought to measure
the amount of b-secretase cleavage taking place only within
the secretory pathway. When APP lacks a cytoplasmic tail
(APPDC), its endocytosis is inhibited (Koo and Squazzo
1994; Perez et al. 1999), and thus, it is restricted to the
secretory pathway. b-secretase cleavage was still detectable
for APPswDC, but the relative amount of secreted APPswb
compared to full-length APPsw was not determined (Citron
et al. 1995). We hypothesized that APPswDC would undergo
less b-secretase cleavage than APPsw, which has access to
b-secretase cleavage in both the secretory and endocytic
pathways. CHOK1 cells were transiently transfected with
empty vector, APPsw or APPswDC. Conditioned media was
collected as previously described and analyzed by ELISA for
APPswb secretion. Surprisingly, rather than a decrease in
b-secretase cleavage, cells expressing the APPswDC mutant
secreted APPswb at significantly higher levels than APPsw
(Fig. 4a). Western blot and densitometric analysis of proteins
immunoprecipitated from cell lysates with 8E5 revealed that
APPsw and APPswDC expression levels were equivalent
(Fig. 4b) and could not account for the increase in b-secre-
tase cleavage of APPswDC. This suggests that the cyto-
plasmic tail of APPsw influences its trafficking and
b-secretase cleavage. Deletion of the carboxyl terminus
Fig. 3 Addition of a dilysine retrieval motif to the carboxyl-terminus of
APPsw significantly decreases APPswb levels in conditioned media.
HEK293 and CHOK1 cells were transiently transfected with pCDNA3,
pCDAPPwt, pCDAPPsw, or pCDAPPswKK as indicated, and condi-
tioned media was collected for APPswb ELISA. (a) Compared to
APPsw, b-secretase cleavage of dilysine-modified APPsw (APPswKK)
decreased secreted APPswb levels in conditioned media by 91% and
86% in HEK293 (j) and CHOK1 cells (h), respectively. (n ¼ 3,
**p < 0.01, ***p < 0.001, Student’s t-test). (b) Lysates from CHOK1
cells used for the #931 ELISA in (a) above were immunoprecipitated
with #931 antisera and immunoblotted with 22C11 to visualize intra-
cellular APPswb (iAPPswb). Compared to cells expressing APPsw
(lane 3), lysates from APPswKK-expressing cells had only 15%
iAPPswb (lane 4). (c) The same lysates used in (b) above were
immunoprecipitated with 8E5 (recognizes epitopes within the amino-
terminal ectodomain of APP) and immunoblotted with 22C11 to visu-
alize full-length APP. Densitometric analysis of this Western blot
confirmed equivalent protein expression levels (data not shown).
Fig. 4 Deletion of the cytoplasmic tail of APPsw causes a significant
increase in b-secretase cleavage. Following transient transfection with
pCDNA3, pCDAPPsw (APPsw), or pCDAPPswDC (APPswDC), con-
ditioned media from CHOK1 cells were collected for APPswb ELISA.
Cellular lysates were immunoprecipitated with 8E5 antibody and
visualized by western blot using 22C11. (a) Compared to APPsw,
expression of the truncated form of APPsw (swDC) causes a 99%
increase in the level of APPswb detected in conditioned media (n ¼ 3,
**p < 0.01, Student’s t-test). (b) Immunoprecipitation of lysates with
an antibody raised to the ectodomain of APP (8E5) followed by
immunoblotting with 22C11 demonstrated that APPswDC expression
is similar to that for APPsw in CHOK1 cells (confirmed by densito-
metry, data not shown).
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makes APPswDC more vulnerable to b-secretase cleavage
within the secretory pathway.
Several proteins have been reported to bind to different
regions of the cytoplasmic tail of APP (Nishimoto et al.
1993; Borg et al. 1996; Chow et al. 1996; Guenette et al.
1996; Homayouni et al. 1999). The exact functions of these
interactions remain to be determined. Deletion of the
cytoplasmic tail not only disrupts endocytosis, but also
prevents the interactions of these APP binding proteins. On
the other hand, the increase in secreted APPswb may be
because a b-secretase is present at or near the cell surface to
cleave APPswDC molecules that accumulate there due to a
block in endocytosis. If this latter explanation were true, then
specific point mutations known to disrupt endocytosis of
APP should also elevate APPswb secretion as observed for
APPswDC. Therefore, additional experiments were conduc-
ted to measure the effect these specific point mutants that
impair APP endocytosis have on APPswb secretion.
Cytoplasmic tail point mutations that block endocytosis
have little or no effect on b-secretase cleavage of APPsw. It
has been demonstrated that a block in endocytosis was
produced when specific mutations (N740A or P741A; Fig. 5)
were made in the carboxyl terminus of APP (Perez et al.
1999). Therefore, we sought to measure b-secretase cleavage
of APPsw in the secretory versus the endocytic pathways by
expressing these endocytic point mutants in different cell
types and measuring secreted APPswb. We reasoned that
such specific point mutations would block endocytosis
without completely disrupting binding of all cytoplasmic
proteins to other regions of the carboxyl terminus as occurred
with the APPswDC deletion mutant. Thus, experiments were
conducted in which HEK293 and N2a (Fig. 6) cells were
transiently transfected with pCDNA3, APPsw, APPswDC,
APPswN740A or APPswP741A. Conditioned media and cell
lysates were collected for ELISA analysis of APPswb and
full-length APPsw, respectively. Mutations within the YENP
internalization signal of APPsw that block endocytosis
(Perez et al. 1999) did not greatly affect b-secretase
cleavage (Fig. 6). Unlike APPswDC, cells expressing the
APPswN740A or APPswP741A point mutants did not
elevate APPswb levels in the conditioned medium. Instead,
the amount of APPswb secreted by HEK cells expressing
APPswP741A was not significantly different from that
secreted by cells expressing APPsw. Surprisingly, a repro-
ducible increase in APPswb secretion was detected when
APPswP741A was expressed in the neuroblastoma cell line,
N2a.
Compared to APPsw, the APPswN740A mutation
decreased APPswb secretion in both cell types. In fact, in
HEK293 cells, the amount of b-secretase cleavage detected
with the APPswN740A mutant was about 65% of APPsw.
Fig. 5 Location of antibody recognition sites within APPsw and sites
of mutagenic modifications. Antibody recognition sites are indicated
above and below the schematic of APPsw (APP751 numbering). The
K651M/N652L mutation of APP to generate APPsw is shown in bold at
the b-secretase cleavage site. The last 20 amino acids of APPsw are
enlarged to illustrate the position of the three point mutations within the
YENP internalization signal, as well as the location of the dilysine (KK)
mutation. The APPswDC mutant lacks all but four amino acid residues
of the entire cytoplasmic tail (truncated from Y709 to N751). TMD,
transmembrane domain; Ab, amyloid-b peptide; a b c, arrows indicate
a-, b-, c-secretase cleavage sites.
Fig. 6 Point mutations in the endocytic signal sequence within the
cytoplasmic tail of APPsw do not significantly affect b-secretase
cleavage or Ab40 peptide generation. HEK293 cells were transiently
transfected with the following: pCDNA, pCDAPPsw (APPsw),
pCDAPPswN740A (swN740A), pCDAPPswP741A (swP741A), and
pCDAPPswDC (swDC). Conditioned media were collected for both
APPswb- and Ab-ELISA analysis. Data are plotted relative to APPsw
(APPsw ¼ 1.0). The percent changes were calculated after subtracting
the signal obtained with empty vector. Compared to APPsw, expres-
sion of the truncated APPsw mutant (swDC) resulted in a 107%
increase in APPswb levels (white bars) (n ¼ 3, p < 0.08, Student’s
t-test). Conversely, the swN740A and the swP741A mutants have
levels of APPswb, respectively, corresponding to a 30% decrease and
a negligible 4% decrease, compared to APPsw. Ab ELISA analysis
(n ¼ 3) of conditioned media closely corresponded with that for
APPswb. Compared to APPsw, swDC has an increase in Ab peptide
production of 305% (**p < 0.01, Student’s t-test). The swN740A
mutant produces only 48% of the Ab peptide production obtained with
APPsw. The swP741A mutant had an insignificant decrease in Ab
compared to APPsw. Full-length protein expression (data not shown)
of the three point mutants and the C-terminal truncation were equi-
valent to APPsw. N2a (black bars, n ¼ 3) cells were transfected as
described for HEK cells. The conditioned media were analyzed by
APPswb ELISA. Data are plotted relative to APPsw (APPsw ¼ 1.0).
For most samples, N2a cells produced the same levels of APPswb
relative to APPsw as in HEK293 cells. However, a significant increase
in APPswb (65%) in N2a cells, compared to APPsw. (**p < 0.01,
Student’s t-test).
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Thus, our results indicate that b-secretase cleavage of APPsw
through the endocytic pathway accounts for no more than
35% of the cleavage that takes place in these cells. Lysates of
N2a cells were tested for full-length protein expression using
the #945 ELISA and western blot analysis. The differences in
APPswb levels measured in our #931 ELISA of conditioned
media were not due to differences in expression levels of the
different point mutants of APPsw. Cross-reactivity with
endogenous human APP prevented measuring full-length
protein levels in HEK293 cells.
The effect of endocytosis mutations on secreted Ab40
produced by transiently transfected cells
In Fig. 6, we demonstrated that point mutations in the
cytoplasmic tail that blocked endocytosis did not strongly
influence b-secretase cleavage of APPsw. On the other hand,
deletion of the entire cytoplasmic tail significantly increased
b-secretase cleavage of APPsw. Experiments were next
conducted to determine if these same point and deletion
mutations had similar affects on Ab40 secretion, as would be
predicted. HEK293 cells were transiently transfected with
empty vector, APPsw, or the APPsw C-terminal mutants and
the resulting conditioned media were analyzed by ELISA for
Ab40. The Ab42 levels were below the threshold for
detection. The levels of Ab40 (Fig. 6, black bars) released
into the media from the endocytosis-impaired APPsw
mutants were found to closely parallel the ELISA results
described for secreted APPswb (Fig. 6, white bars). Cells
expressing APPswDC produced a significantly increased
amount of Ab40 compared to APPsw-expressing cells. The
amount of Ab40 generated by the endocytosis mutant,
APPswP741A, did not significantly differ from that gener-
ated by APPsw. Finally, as observed for APPswb secretion,
cells expressing APPswN740A produces a slight, but
statistically insignificant decrease in Ab40. Thus, mutations
that increase or decrease secretion of APPswb as measured
by our ELISA resulted in a corresponding and proportional
change in Ab40 production.
Discussion
Ab peptides are produced from APP at several different
locations within the cell. The experiments presented here
determined the relative importance these distinct cellular
locations have in contributing to the amount of b-secretase-
cleaved soluble product, APPswb, which is secreted into the
media. Ab peptides are reportedly derived as early as the
endoplasmic reticulum (Cook et al. 1997; Wild-Bode et al.
1997; Skovronsky et al. 1998; Annaert et al. 1999). This
would suggest that both b- and c-secretase cleave APP early
in the secretory pathway. Presenilins, which are closely
associated with c-secretase activity, are predominantly
located in the ER and Golgi compartments (Xia et al.
1998). Thus, they could be responsible for the carboxyl
terminal cleavage necessary to generate Ab peptide in the ER
or intermediate compartment. However, the recently cloned
b-secretase, BACE1, primarily localizes to the Golgi appar-
atus, trans Golgi network and possibly endosomes (Vassar
et al. 1999). Two explanations for the b-secretase activity in
the ER have been proposed: either APP is cleaved at the
amino terminus by a novel b-secretase in the ER that is
distinct from BACE1 (Chyung et al. 1997) or there is a low
level of BACE activity in this compartment (Annaert et al.
1999). Regardless of which is correct, the relative amount of
b-secretase cleavage occurring in the ER has not been
previously measured.
To measure ER b-secretase activity, we introduced an ER
retrieval signal to the cytoplasmic tail of APP and APPsw.
Others have introduced this dilysine motif to measure the
amount of Ab peptide generated in the ER/IC (Cook et al.
1997; Skovronsky et al. 1998; Annaert et al. 1999). How-
ever, the effectiveness of this motif to retain APP has not
been thoroughly characterized. We found that introduction of
a dilysine retrieval motif extended the half-life of immature
APP by approximately fourfold. The amount of APPswb
secreted by cells expressing APPswKK was significantly
decreased to between 9 and 15% of that secreted by cells
expressing APPsw. Yet, it was not completely eliminated. We
previously reported that binding of a mutant of the ER
resident molecular chaperone, BiP, to either APP or APPsw
significantly inhibited secretion of Ab40 and Ab42 (Yang
et al. 1998). Retention of APPsw in the ER through binding
mutant BiP may explain the decrease in Ab peptide secretion
that we previously observed if this effect was a result of
blocking movement to the site of b- or c-secretase cleavage
(Yang et al. 1998). When HEK cells were transfected with
mutant BiP and APPsw, a significant decrease in APPswb
secretion similar to that obtained with APPswKK transfec-
tion (data not shown). Thus, we show for the first time that
the maximal amount of b-secretase cleavage that takes place
in the ER is less than 14% of the total cleavage detected.
Analysis of cell lysates revealed a similar amount (15%) of
intracellular APPswb present in cells expressing APPswKK
compared to APPsw. This latter observation indicates that
b-secretase cleavage of APPswKK does not create a separate
intracellular pool of APPswb. This result also confirms the
measurements obtained for secreted APPswb by ELISA for
cleavage of APPswKK in the ER.
There is another explanation for these results besides
b-cleavage occurring in the early secretory pathway.
Although no fully glycosylated APPsw protein was detected
(see Fig. 2), some APPswKK molecules may escape the
cellular mechanisms of ER retention to be cleaved in the
Golgi by BACE. Therefore, the 15% of b-secretase cleavage
measured here must be considered as the maximum amount
of cleavage that could occur in the ER/IC. Nevertheless, this
amount of b-secretase cleavage may be significant, if the
resulting carboxyl terminal fragment were preferentially
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converted to the more amyloidogenic, Ab42 peptide. Results
of others indicate that this might be the case. Treating cells
with brefeldin A (BFA) blocks secretion and redistributes the
Golgi into the ER (Doms et al. 1989; Lippincott-Schwartz
et al. 1989). Incubation of HEK293 cells stably expressing
APP with BFA increased intracellular levels of Ab1–42 and
Abx)42 (Wild-Bode et al. 1997). Similarly, BFA treatment
of human NT2 neurons blocked production of intracellular
Ab40, but not Ab1–42 (Cook et al. 1997). Immunostaining
and electron microscopic examination of primary hippocam-
pal neurons also identified the ER as a site of Ab1–42
generation (Hartmann et al. 1997). Still other results using
NT2 neurons expressing APPKK demonstrate that a large
portion of the intracellular Ab1–42 generated in the ER/IC is
an insoluble pool (Skovronsky et al. 1998). Thus, while the
amount of b-secretase cleavage of APPsw we detect in the
ER/IC may be low, its role in the pathogenesis of Alzhei-
mer’s disease requires further investigation.
While conducting ELISA analysis, we found that APPswb
secretion exactly mirrored Ab secretion. Since Ab peptide
generation requires b- followed by c-secretase cleavage,
b-secretase cleavage indirectly regulates c-secretase cleavage
of APP and Ab generation. This makes our findings
regarding b-secretase cleavage in the secretory and endocytic
pathway especially pertinent to therapeutic intervention
strategies. In fact, our observation is consistent with
b-secretase cleavage of APP being the rate-limiting step of
in vivo Ab production (Sinha and Lieberburg 1999). In
addition to the utility of the #931 ELISA to measure
APPswb, it is possible that this ELISA may serve as a proxy
for measuring Ab.
APP and APPsw processing into Ab peptides in non-
neuronal cells appears to utilize different cellular mecha-
nisms. Radiolabeling of cell surface APP in CHO cells
revealed that amyloid peptide could be derived through
endocytosis (Koo and Squazzo 1994). Furthermore, deletion
of the carboxyl terminal tail from APP to block endocytosis
strongly inhibits Ab peptide secretion. On the other hand,
when similarly truncated APPsw is expressed in HEK293
cells, Ab peptide is still detected in conditioned media
(Citron et al. 1995). This implies that APPsw could be
cleaved within the secretory pathway. Yet, APPsw processing
into Ab peptide occurs through the endocytic pathway in
addition to the secretory pathway (Perez et al. 1996).
Moreover, cell surface-radioiodination of APPsw molecules
resulted in the release of twofold more iodinated Ab peptide
compared to APP (Perez et al. 1996). The proportion of Ab
derived from APPsw processing in the secretory pathway
compared to the endocytic pathway has not been previously
determined. Therefore, we measured the amount of APPswb
and Ab40 secreted by cells expressing endocytosis-impaired
mutants of APPsw and compared them to normal APPsw.
Endocytosis of APP is dependent on a highly conserved
signal sequence within its cytoplasmic tail (Koo and Squazzo
1994). Two residues, N740 and P741, are part of the YXNP
motif important for endocytosis of APP (Perez et al. 1999).
Internalization of full-length APP is significantly impaired
when either of these residues in the cytoplasmic tail is
mutated to alanine (Perez et al. 1999). In fact, the N740A
mutant is as effective as deleting the entire cytoplasmic
domain at impeding endocytosis. The block in endocytosis
by these point mutants, in turn, caused a substantial reduction
in the amount of secreted Ab peptide compared to wild-type
APP. Consequently, we introduced these same point mutants
into APPsw to block its endocytosis. When expressed in
HEK293 cells, APPswP741A had little or no effect on
APPswb secretion. Curiously, a slight increase in APPswb
secretion was reproducibly measured in N2a cells expressing
APPswP741A, suggesting that this mutation has an effect on
neuronal-specific cytoplasmic proteins. As mentioned, the
N740A mutation more severely impaired endocytosis of APP
than did the P741A mutation (Perez et al. 1996). This may
explain why, compared to APPsw-expressing cells, APPswb
secretion was lower in cells expressing APPswN740A but
not in cells expressing APPswP741A. In HEK293 cells, this
decrease was 30%. This decrease in b-secretase cleavage
of APPswN740A resulted in a corresponding decrease in
secreted Ab40. These results indicate that the amount of
b-secretase cleavage of APPsw taking place within the
endocytic pathway is not more than one-third of the total
activity within these cells. However, it should be noted that
our ELISA specifically recognizes APPswb cleaved between
L671 and D672. b-secretase cleavage that occurs at alternate
sites would not be captured by the #931 antibody. Therefore,
if endocytosed APPsw is cleaved at such alternate sites, then
our ELISA would not detect this activity. We conclude from
these studies that b-secretase cleavage of APPsw does occur
within the endocytic pathway as reported (Perez et al. 1996).
However, our results indicate that the majority of b-secretase
cleavage of APPsw occurs in compartments of the late
secretory pathway.
Like the point mutations in the YENP protein binding
motif, deletion of the cytoplasmic domain of APP (APPDC)
strongly impairs endocytosis (Perez et al. 1999). Surprisingly,
we discovered that the same deletion in APPsw (APPswDC)
significantly increased Ab40 secretion compared to full-
length APPsw. We also observed a corresponding increase in
the amount of APPswb secreted by cells expressing
APPswDC compared to those expressing APPsw. Others,
who have previously observed that APPswDC-expressing
cells secreted Ab peptide, did not report such an increase
(Citron et al. 1995). Western blot analysis does not indicate
any difference in the amount of intact APPswDC compared
to full-length APPsw. It is possible that deletion of the
cytoplasmic tail interferes with insertion of APPswDC into
the membrane, making it more vulnerable to b-cleavage.
Alternatively, deletion of the cytoplasmic tail from APPsw
could make APPswDC more susceptible to b-secretase
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cleavage. This, in turn, could lead to increased Ab40
generation. Such an increased susceptibility to b-secretase
can not involve endocytosis since this effect was not
observed with the N740A or P741A point mutants. A
number of cytoplasmic proteins have been reported to bind to
the exposed carboxyl terminal tail of APP (Nishimoto et al.
1993; Borg et al. 1996; Chow et al. 1996; Guenette et al.
1996; Homayouni et al. 1999). Mutations in the YENP
sequence within the APP tail are reported to alter binding of
two such cytoplasmic proteins: FE65 and X11 (Borg et al.
1996; Guenette et al. 1996). The role of these interacting
proteins in APP processing is unclear. We hypothesize that
such an endogenous protein binds to the cytoplasmic tail of
APPsw making it less vulnerable to b-secretase cleavage. We
speculate that C-terminal–protein interactions may be espe-
cially important for manifesting this shielding effect as
APPsw is processed through the secretory pathway. Experi-
ments are currently underway in our laboratory to explore
this hypothesis.
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